Comparative Pharmacology
Head-to-head clinical analysis: PFIZERPEN AS versus PFIZERPEN VK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PFIZERPEN AS versus PFIZERPEN VK.
PFIZERPEN-AS vs PFIZERPEN VK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
PFIZERPEN-AS (penicillin G procaine) inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and transglycosylation, leading to cell lysis.
Penicillin V binds to penicillin-binding proteins (PBPs) located on the bacterial cell wall, inhibiting transpeptidase activity and disrupting peptidoglycan cross-linking, leading to cell lysis via autolytic enzymes.
250-500 mg orally every 6-8 hours for moderate infections; 500 mg to 2 g intravenously every 4-6 hours for severe infections.
250-500 mg orally every 6 hours for mild to moderate infections; 500 mg orally every 6 hours for severe infections. For group A streptococcal pharyngitis: 250 mg orally 3 times daily or 500 mg twice daily for 10 days.
None Documented
None Documented
0.5-1 hour in healthy adults; prolonged to 2.5-10 hours in renal impairment (CrCl <10 mL/min). Clinically relevant for dosing interval adjustment in renal dysfunction.
Terminal half-life: 30–60 minutes in adults with normal renal function; prolonged in renal impairment (up to 4–10 hours in anuria).
Primarily renal (60-80% as unchanged drug via tubular secretion and glomerular filtration); minor biliary/fecal elimination (10-20%)
Renal: ~60-80% unchanged via tubular secretion; biliary/fecal: minor (hepatic elimination of metabolites).
Category C
Category C
Antibiotic (Penicillin)
Antibiotic (Penicillin)